Hospital
Phc-Las Cruces INC
Phc-Las Cruces INC was paid $64.77M by Medicaid between Jan 2018 and Dec 2024, across 468 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoPHC-LAS CRUCES INC
LAS CRUCES, NM 88011
LAS CRUCES, NM 88011
33aNPI1700821808assigned 06/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$64.77M
24GClaims1,518,990
24DCodes billed468
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#2 of 24
Median peer was paid$20.13M
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 309,579 | $11.95M | |
| 2019 | 217,930 | $8.30M | |
| 2020 | 150,813 | $6.27M | |
| 2021 | 168,421 | $7.28M | |
| 2022 | 210,740 | $9.08M | |
| 2023 | 258,262 | $11.92M | |
| 2024incomplete | 203,245 | $9.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 53,042 | 49,915 | $7.59M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.6% | 33,763 | 31,447 | $6.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 12,498 | 11,391 | $3.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 8,046 | 7,523 | $2.84M |
| G0378 | Hospital observation service, per hour | 3.6% | 12,722 | 7,264 | $2.35M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 10,224 | 9,466 | $1.96M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.0% | 32,081 | 28,996 | $1.93M |
| 80053 | Comprehensive metabolic panel | 2.5% | 123,318 | 104,020 | $1.63M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 16,462 | 15,686 | $1.54M |
| 71045 | Radiologic examination, chest; single view | 2.4% | 25,920 | 23,683 | $1.54M |
| D2930 | Prefabricated stainless steel crown - primary tooth | 1.7% | 8,601 | 1,623 | $1.08M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 4,074 | 3,760 | $1.07M |
456 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 122,078 | $918K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 10,492 | $831K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.2% | 2,066 | $767K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.2% | 475 | $762K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 1,904 | $735K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 11,157 | $730K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 2,355 | $661K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 15,321 | $651K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,043 | $601K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,209 | $590K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,655 | $579K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,571 | $565K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,286 | $538K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 30,844 | $537K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,978 | $506K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,405 | $503K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,355 | $485K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,693 | $475K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,686 | $474K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,261 | $448K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,084 | $442K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,445 | $428K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,294 | $389K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,448 | $373K |
| 93458 | <1% | 209 | $314K | |
| 80061 | Lipid panel | <1% | 21,607 | $310K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,636 | $306K |
| D2330 | <1% | 2,247 | $301K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15,768 | $290K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,166 | $288K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 635 | $277K |
| 76830 | Ultrasound, transvaginal | <1% | 2,467 | $259K |
| 83690 | <1% | 25,156 | $253K | |
| 70486 | <1% | 1,276 | $252K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,250 | $251K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 946 | $245K |
| 84484 | <1% | 20,930 | $243K | |
| 81001 | <1% | 44,527 | $235K | |
| 96367 | <1% | 3,747 | $225K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 176 | $219K |
| 76641 | <1% | 2,137 | $213K | |
| 73562 | <1% | 2,661 | $210K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,190 | $207K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,296 | $197K |
| 76801 | <1% | 1,702 | $196K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,829 | $195K |
| 72100 | <1% | 2,275 | $188K | |
| 73030 | <1% | 2,340 | $186K | |
| 73130 | <1% | 2,413 | $184K | |
| 73610 | <1% | 1,761 | $176K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,651 | $172K |
| 87088 | <1% | 17,964 | $169K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,694 | $167K |
| D1206 | Topical application of fluoride varnish | <1% | 1,360 | $165K |
| 77336 | <1% | 1,537 | $165K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 20,840 | $164K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,162 | $155K |
| 36415 | Collection of venous blood by venipuncture | <1% | 43,328 | $152K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 268 | $149K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,498 | $145K |
| 73630 | <1% | 2,024 | $144K | |
| 84703 | <1% | 9,708 | $140K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,838 | $139K |
| 73221 | <1% | 454 | $139K | |
| 84145 | <1% | 4,677 | $136K | |
| 74178 | <1% | 560 | $136K | |
| 87040 | <1% | 9,795 | $136K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 332 | $136K |
| 59025 | Fetal non-stress test | <1% | 1,386 | $134K |
| 70496 | <1% | 463 | $131K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,621 | $129K |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 1,003 | $123K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,209 | $122K |
| 77386 | <1% | 320 | $121K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,134 | $120K |
| 88312 | <1% | 1,687 | $116K | |
| 74018 | <1% | 1,925 | $113K | |
| 71250 | <1% | 896 | $111K | |
| 93971 | <1% | 1,364 | $108K | |
| 99152 | <1% | 2,099 | $106K | |
| 86703 | <1% | 6,134 | $104K | |
| 84702 | <1% | 5,342 | $104K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 15 | $103K |
| 80074 | <1% | 2,248 | $102K | |
| 85610 | <1% | 26,218 | $98K | |
| 88304 | <1% | 2,982 | $98K | |
| 73110 | <1% | 1,262 | $97K | |
| 83880 | <1% | 4,656 | $96K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 39 | $96K |
| 77334 | <1% | 254 | $95K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,563 | $95K |
| 72131 | <1% | 551 | $94K | |
| 74246 | <1% | 1,022 | $92K | |
| 87070 | <1% | 8,186 | $89K | |
| 76536 | <1% | 971 | $89K | |
| 82728 | <1% | 5,938 | $87K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,025 | $87K |
| 76770 | <1% | 1,019 | $86K | |
| 70491 | <1% | 304 | $85K | |
| 47563 | <1% | 38 | $84K | |
| 87430 | <1% | 5,238 | $82K | |
| 70498 | <1% | 416 | $81K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,717 | $81K |
| 85027 | <1% | 10,410 | $80K | |
| 47562 | <1% | 25 | $79K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 842 | $79K |
| 86780 | <1% | 5,079 | $76K | |
| 83605 | <1% | 7,724 | $74K | |
| C1776 | Joint device (implantable) | <1% | 87 | $72K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 115 | $70K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,022 | $70K |
| 87186 | <1% | 8,127 | $70K | |
| 77080 | <1% | 1,085 | $69K | |
| 84439 | <1% | 6,019 | $68K | |
| 49083 | <1% | 281 | $65K | |
| 0002A | <1% | 1,407 | $62K | |
| 86140 | <1% | 7,737 | $61K | |
| 82962 | <1% | 24,639 | $61K | |
| 91200 | <1% | 490 | $61K | |
| 82607 | <1% | 4,951 | $58K | |
| 72040 | <1% | 728 | $58K | |
| D1120 | Dental cleaning, child | <1% | 494 | $57K |
| 77412 | <1% | 496 | $56K | |
| 97597 | <1% | 977 | $56K | |
| 96417 | <1% | 1,191 | $56K | |
| 83735 | <1% | 8,498 | $55K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 490 | $55K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,910 | $54K |
| 76881 | <1% | 527 | $52K | |
| D2929 | <1% | 484 | $50K | |
| 0001A | <1% | 1,387 | $49K | |
| 87486 | <1% | 2,092 | $48K | |
| 87581 | <1% | 2,092 | $48K | |
| 81514 | <1% | 331 | $48K | |
| 88307 | <1% | 247 | $46K | |
| 87150 | <1% | 1,227 | $46K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16,605 | $46K |
| 76000 | <1% | 271 | $45K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,225 | $45K |
| 85730 | <1% | 9,303 | $44K | |
| 76870 | <1% | 449 | $44K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,483 | $44K |
| 93017 | <1% | 379 | $43K | |
| 86803 | <1% | 3,464 | $43K | |
| 73090 | <1% | 568 | $43K | |
| 83540 | <1% | 5,934 | $43K | |
| 75574 | <1% | 188 | $42K | |
| 81025 | <1% | 5,573 | $41K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 165 | $40K |
| 87081 | <1% | 4,349 | $40K | |
| 84481 | <1% | 2,467 | $38K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,642 | $38K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,653 | $37K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,393 | $37K |
| 99153 | Mod sedat endo service >5yrs | <1% | 790 | $37K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,649 | $36K |
| 77066 | Tomosynthesis, mammo | <1% | 334 | $36K |
| D7240 | Removal of impacted tooth - completely bony | <1% | 215 | $35K |
| 80055 | <1% | 731 | $35K | |
| 76642 | <1% | 380 | $35K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,858 | $34K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 294 | $33K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,223 | $33K |
| 86850 | <1% | 4,875 | $33K | |
| 88342 | <1% | 827 | $33K | |
| 78306 | <1% | 174 | $33K | |
| 73590 | <1% | 492 | $32K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,119 | $31K |
| 82803 | <1% | 1,246 | $31K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,811 | $31K |
| 73120 | <1% | 436 | $31K | |
| 82570 | <1% | 5,330 | $30K | |
| 82746 | <1% | 2,831 | $30K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,553 | $30K |
| 86787 | <1% | 1,635 | $30K | |
| 91035 | <1% | 125 | $29K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 266 | $28K |
| 93970 | <1% | 266 | $28K | |
| 86920 | <1% | 340 | $28K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 51 | $27K |
| 74019 | <1% | 346 | $27K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,739 | $27K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,469 | $27K |
| 86900 | <1% | 6,315 | $27K | |
| 84425 | <1% | 1,278 | $26K | |
| 72072 | <1% | 329 | $26K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 641 | $26K |
| 36430 | <1% | 198 | $25K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 351 | $25K |
| 86901 | <1% | 6,309 | $24K | |
| 84403 | <1% | 981 | $23K | |
| 77065 | Tomosynthesis, mammo | <1% | 309 | $23K |
| 82105 | <1% | 1,267 | $23K | |
| 72141 | <1% | 94 | $23K | |
| 96415 | <1% | 476 | $22K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 145 | $22K |
| 73502 | <1% | 758 | $22K | |
| 86038 | <1% | 1,666 | $22K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 285 | $22K |
| 29125 | <1% | 213 | $22K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,230 | $21K |
| 85651 | <1% | 5,544 | $21K | |
| 84597 | <1% | 1,202 | $21K | |
| 77300 | <1% | 132 | $20K | |
| 84436 | <1% | 2,086 | $20K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 44 | $19K |
| 87340 | <1% | 2,371 | $19K | |
| 86003 | <1% | 122 | $18K | |
| 84153 | <1% | 1,919 | $18K | |
| 73070 | <1% | 350 | $18K | |
| 91010 | <1% | 51 | $17K | |
| 83001 | <1% | 850 | $17K | |
| 86762 | <1% | 1,282 | $17K | |
| 87205 | <1% | 3,377 | $17K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,121 | $17K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 336 | $17K |
| 87653 | <1% | 468 | $17K | |
| 84446 | <1% | 1,225 | $17K | |
| 82043 | <1% | 3,176 | $17K | |
| 87522 | Neg quan hep c or qual rna | <1% | 306 | $17K |
| 36591 | <1% | 555 | $17K | |
| 84100 | <1% | 3,495 | $17K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,332 | $16K |
| 83615 | <1% | 2,026 | $16K | |
| D1351 | Sealant - per tooth | <1% | 179 | $16K |
| 96376 | <1% | 1,485 | $16K | |
| 83970 | <1% | 589 | $15K | |
| 83520 | <1% | 408 | $15K | |
| 73620 | <1% | 290 | $15K | |
| C1762 | Connective tissue, human (includes fascia lata) | <1% | 41 | $14K |
| 72170 | <1% | 238 | $14K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 7,360 | $14K |
| 80076 | <1% | 1,276 | $13K | |
| 87490 | <1% | 579 | $13K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 101 | $13K |
| 73560 | <1% | 261 | $13K | |
| 87590 | <1% | 579 | $13K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,608 | $13K |
| 87641 | <1% | 753 | $13K | |
| 73100 | <1% | 231 | $13K | |
| 84156 | <1% | 2,273 | $12K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,420 | $12K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 773 | $12K |
| 82784 | <1% | 794 | $12K | |
| 74220 | <1% | 110 | $12K | |
| 85378 | <1% | 1,803 | $11K | |
| 83525 | <1% | 1,038 | $11K | |
| 82550 | <1% | 1,560 | $11K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,068 | $11K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 796 | $11K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,377 | $11K |
| 71100 | <1% | 199 | $11K | |
| 87536 | <1% | 126 | $10K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $10K |
| 81002 | <1% | 1,845 | $10K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,185 | $10K |
| 84550 | <1% | 1,946 | $10K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 939 | $10K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,693 | $10K |
| 87075 | <1% | 1,203 | $10K | |
| 88142 | <1% | 594 | $10K | |
| 83002 | <1% | 488 | $10K | |
| 84402 | <1% | 415 | $10K | |
| 84146 | <1% | 447 | $9K | |
| 12002 | <1% | 119 | $9K | |
| D2331 | <1% | 83 | $9K | |
| 84466 | <1% | 911 | $9K | |
| A9270 | Non-covered item or service | <1% | 5,157 | $9K |
| 82150 | <1% | 1,162 | $9K | |
| 73080 | <1% | 124 | $8K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 573 | $8K |
| 86235 | <1% | 126 | $8K | |
| 88300 | <1% | 715 | $8K | |
| 12001 | <1% | 75 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 165 | $8K |
| 43235 | <1% | 13 | $7K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,412 | $7K |
| 86431 | <1% | 926 | $7K | |
| 90715 | <1% | 371 | $7K | |
| 96402 | <1% | 277 | $7K | |
| 90714 | <1% | 497 | $7K | |
| 84560 | <1% | 1,253 | $7K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,644 | $7K |
| 84479 | <1% | 820 | $6K | |
| 10060 | <1% | 61 | $6K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,473 | $6K |
| 82248 | <1% | 1,049 | $6K | |
| 84144 | <1% | 366 | $6K | |
| J1447 | Injection, tbo-filgrastim, 1 microgram | <1% | 52 | $6K |
| 19083 | <1% | 15 | $6K | |
| 85007 | <1% | 2,564 | $6K | |
| 84480 | <1% | 472 | $6K | |
| 73700 | <1% | 24 | $6K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,357 | $6K |
| 83655 | <1% | 363 | $6K | |
| 86200 | <1% | 373 | $6K | |
| 82140 | <1% | 514 | $5K | |
| 96523 | <1% | 236 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,484 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,320 | $5K |
| 97116 | <1% | 583 | $5K | |
| 88341 | <1% | 328 | $5K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 173 | $5K |
| 72128 | <1% | 30 | $5K | |
| 99156 | <1% | 233 | $5K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 323 | $5K |
| 82950 | <1% | 781 | $4K | |
| 82330 | <1% | 505 | $4K | |
| 97162 | <1% | 191 | $4K | |
| 82247 | <1% | 635 | $4K | |
| 84207 | <1% | 189 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $4K |
| 76937 | <1% | 125 | $4K | |
| 97161 | <1% | 267 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $4K |
| 82553 | <1% | 434 | $4K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 41 | $4K |
| 83516 | <1% | 158 | $4K | |
| 84030 | <1% | 650 | $4K | |
| 82274 | <1% | 363 | $4K | |
| 73060 | <1% | 66 | $3K | |
| 31575 | <1% | 26 | $3K | |
| 0240U | <1% | 145 | $3K | |
| 51702 | <1% | 71 | $3K | |
| 74160 | <1% | 13 | $3K | |
| 87210 | <1% | 449 | $3K | |
| 82677 | <1% | 115 | $3K | |
| 83021 | <1% | 198 | $3K | |
| 86706 | <1% | 219 | $3K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 78 | $3K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 25 | $3K |
| 74230 | <1% | 40 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 378 | $3K |
| 86360 | <1% | 58 | $3K | |
| 91037 | <1% | 24 | $3K | |
| 86225 | <1% | 159 | $3K | |
| 73552 | <1% | 86 | $3K | |
| 86336 | <1% | 140 | $3K | |
| 80179 | <1% | 144 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 26 | $2K |
| 80143 | <1% | 144 | $2K | |
| 80164 | <1% | 148 | $2K | |
| 83020 | <1% | 233 | $2K | |
| 82785 | <1% | 130 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 338 | $2K |
| 74170 | <1% | 12 | $2K | |
| 78227 | <1% | 12 | $2K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 27 | $2K |
| 86255 | <1% | 170 | $2K | |
| 86376 | <1% | 159 | $2K | |
| 92611 | <1% | 40 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 42 | $2K |
| 82670 | <1% | 76 | $2K | |
| 84132 | <1% | 483 | $2K | |
| 87899 | <1% | 55 | $2K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 37 | $2K |
| 82951 | <1% | 122 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,654 | $2K |
| 86696 | <1% | 56 | $2K | |
| 87507 | <1% | 273 | $2K | |
| 86695 | <1% | 112 | $2K | |
| 82310 | <1% | 491 | $2K | |
| 88313 | <1% | 29 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 210 | $2K |
| 87631 | <1% | 64 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,111 | $2K |
| 97165 | <1% | 97 | $2K | |
| 82010 | <1% | 234 | $2K | |
| 82652 | <1% | 49 | $2K | |
| 90656 | <1% | 138 | $2K | |
| 80069 | <1% | 233 | $1K | |
| 85014 | <1% | 750 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,013 | $1K |
| 85660 | <1% | 198 | $1K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 14 | $1K |
| 99188 | <1% | 122 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 208 | $1K |
| 86592 | <1% | 213 | $1K | |
| 91040 | <1% | 12 | $1K | |
| 96368 | <1% | 89 | $1K | |
| 97166 | <1% | 28 | $1K | |
| 94060 | <1% | 17 | $1K | |
| 84134 | <1% | 141 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,483 | $1K |
| 12011 | <1% | 15 | $1K | |
| 76942 | <1% | 15 | $1K | |
| 84295 | <1% | 302 | $1K | |
| 73600 | <1% | 16 | $1K | |
| 94729 | <1% | 17 | $1K | |
| 99157 | <1% | 82 | $1K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 138 | $1K |
| 82565 | <1% | 156 | $1K | |
| 87338 | <1% | 80 | $987.45 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 165 | $944.61 |
| 70360 | <1% | 16 | $913.96 | |
| 85652 | <1% | 568 | $878.92 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 134 | $868.93 |
| 87045 | <1% | 67 | $852.31 | |
| 84112 | <1% | 14 | $847.20 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 47 | $833.04 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 134 | $804.49 |
| 82378 | <1% | 65 | $776.08 | |
| 86160 | <1% | 27 | $759.98 | |
| 80178 | <1% | 94 | $748.55 | |
| 73521 | <1% | 12 | $738.49 | |
| 82533 | <1% | 29 | $721.35 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 286 | $714.01 |
| 86147 | <1% | 12 | $699.65 | |
| 36600 | <1% | 67 | $680.45 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 249 | $666.79 |
| 94727 | <1% | 17 | $665.06 | |
| 86665 | <1% | 16 | $636.18 | |
| 84154 | <1% | 74 | $600.86 | |
| 74021 | <1% | 12 | $587.91 | |
| G0008 | Administration of influenza virus vaccine | <1% | 44 | $584.86 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 288 | $575.36 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 147 | $531.01 |
| 77081 | <1% | 25 | $524.80 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 59 | $515.79 |
| 86308 | <1% | 65 | $511.82 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 62 | $496.35 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 63 | $440.80 |
| 82947 | <1% | 79 | $432.50 | |
| 84165 | <1% | 38 | $417.10 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 92 | $368.17 |
| 87807 | <1% | 37 | $333.59 | |
| V2632 | Posterior chamber intraocular lens | <1% | 205 | $309.37 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 502 | $302.27 |
| 84442 | <1% | 25 | $294.80 | |
| 82977 | <1% | 38 | $286.05 | |
| 86664 | <1% | 15 | $284.86 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 76 | $267.07 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 33 | $260.55 |
| 85046 | <1% | 60 | $254.99 | |
| 82365 | <1% | 26 | $242.76 | |
| 83883 | <1% | 17 | $232.98 | |
| 86704 | <1% | 15 | $199.63 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 241 | $198.80 |
| C9088 | Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg | <1% | 14 | $190.35 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 134 | $166.57 |
| 86800 | <1% | 13 | $163.35 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 19 | $162.63 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 16 | $151.72 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 87 | $144.10 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 46 | $139.83 |
| 83550 | <1% | 15 | $127.64 | |
| 85018 | <1% | 69 | $121.10 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 32 | $111.28 |
| 88311 | <1% | 12 | $89.36 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 62 | $88.39 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 32 | $76.81 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 23 | $61.17 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 57 | $52.57 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 59 | $0.00 |
| 91300 | 0% | 22 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.